Neurocrine Biosciences (NBIX) said Friday the phase 4 study of its Ingrezza treatment for patients with tardive dyskinesia showed improvements in functional and health-related quality of life measures.
Patients with the movement disorder who received the treatment for eight weeks experienced significant improvements in measures such as mobility, self-case, usual activities, and pain/discomfort, the company said.
In a separate analysis, patients who received the treatment also experienced improvements in Sheehan Disability Scale items, including work/school, social life, and family/home life, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。